Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 11/18/24
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should KnowZacks Investment Research • 11/11/24
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. PartnershipsBenzinga • 10/28/24
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100GlobeNewsWire • 10/28/24
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of PresbyopiaGlobeNewsWire • 10/21/24
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of PresbyopiaGlobeNewsWire • 08/12/24
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024GlobeNewsWire • 08/07/24
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/08/24
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024GlobeNewsWire • 05/01/24
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia TrialsBusiness Wire • 04/03/24
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia TrialsBusiness Wire • 04/02/24
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate ProgressBusiness Wire • 03/21/24